Title |
Targeting mTOR in Pancreatic Ductal Adenocarcinoma
|
---|---|
Published in |
Frontiers in oncology, April 2016
|
DOI | 10.3389/fonc.2016.00099 |
Pubmed ID | |
Authors |
Sentia Iriana, Shahzad Ahmed, Jun Gong, Alagappan Anand Annamalai, Richard Tuli, Andrew Eugene Hendifar |
Abstract |
Treatment options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited; however, new therapies targeting specific tumor-related molecular characteristics may help certain patient cohorts. Emerging preclinical data have shown that inhibition of mammalian target of rapamycin (mTOR) in specific KRAS-dependent PDAC subtypes leads to inhibition of tumorigenesis in vitro and in vivo. Early phase II studies of mono-mTOR inhibition have not shown promise. However, studies have shown that combined inhibition of multiple steps along the mTOR signaling pathway may lead to sustained responses by targeting mechanisms of tumor resistance. Coordinated inhibition of mTOR along with specific KRAS-dependent mutations in molecularly defined PDAC subpopulations may offer a viable alternative for treatment in the future. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 68 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 12 | 18% |
Student > Ph. D. Student | 12 | 18% |
Student > Doctoral Student | 8 | 12% |
Student > Master | 8 | 12% |
Student > Bachelor | 5 | 7% |
Other | 6 | 9% |
Unknown | 17 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 20 | 29% |
Medicine and Dentistry | 9 | 13% |
Chemistry | 6 | 9% |
Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
Immunology and Microbiology | 3 | 4% |
Other | 8 | 12% |
Unknown | 18 | 26% |